|
1
|
Löwenberg B, Downing JR and Burnett A:
Acute myeloid leukemia. N Engl J Med. 341:1051–1062. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wolff SN, Herzig RH, Fay JW, Phillips GL,
Lazarus HM, Flexner JM, Stein RS, Greer JP, Cooper B and Herzig GP:
High-dose cytarabine and daunorubicin as consolidation therapy for
acute myeloid leukemia in first remission: Long-term follow-up and
results. J Clin Oncol. 7:1260–1267. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wells RJ, Woods WG, Buckley JD, Odom LF,
Benjamin D, Bernstein I, Betcher D, Feig S, Kim T, Ruymann F, et
al: Treatment of newly diagnosed children and adolescents with
acute myeloid leukemia: A Childrens cancer group study. J Clin
Oncol. 12:2367–2377. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bellacosa A, Kumar CC, Di Cristofano A and
Testa JR: Activation of AKT kinases in cancer: Implications for
therapeutic targeting. Adv Cancer Res. 94:29–86. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kubota Y, Ohnishi H, Kitanaka A, Ishida T
and Tanaka T: Constitutive activation of PI3K is involved in the
spontaneous proliferation of primary acute myeloid leukemia cells:
Direct evidence of PI3K activation. Leukemia. 18:1438–1440. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Min YH, Eom JI, Cheong JW, Maeng HO, Kim
JY, Jeung HK, Lee ST, Lee MH, Hahn JS and Ko YW: Constitutive
phosphorylation of Akt/PKB protein in acute myeloid leukemia: Its
significance as a prognostic variable. Leukemia. 17:995–997. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu Q, Simpson SE, Scialla TJ, Bagg A and
Carroll M: Survival of acute myeloid leukemia cells requires PI3
Kinase activation. Blood. 102:972–980. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhao S, Konopleva M, Cabreira-Hansen M,
Xie Z, Hu W, Milella M, Estrov Z, Mills GB and Andreeff M:
Inhibition of phosphatidylinositol 3-kinase dephosphorylates BAD
and promotes apoptosis in myeloid leukemias. Leukemia. 18:267–275.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Stauffer F, Holzer P and García-Echeverria
C: Blocking the PI3K/PKB pathway in tumor cells. Curr Med Chem
Anticancer Agents. 5:449–462. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brazil DP, Yang ZZ and Hemmings BA:
Advances in protein kinase B signalling: AKTion on multiple fronts.
Trends Biochem Sci. 29:233–242. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hanada M, Feng J and Hemmings BA:
Structure, regulation and function of PKB/AKT-a major therapeutic
target. Biochim Biophys Acta. 1697:3–16. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edlind MP and Hsieh AC: PI3K-AKT-mTOR
signaling in prostate cancer progression and androgen deprivation
therapy resistance. Asian J Androl. 16:378–386. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang P, Liu N, Pang Q, Qu C, Wang B and
Guo H: PI3K/AKT signaling pathway in the regulation of non-small
cell lung cancer radiosensitivity after hypofractionated radiation
therapy. Int J Radia Oncol Biol Physics. 84:(Suppl). S6702012.
View Article : Google Scholar
|
|
14
|
Roche S, Koegl M and Courtneidge SA: The
phosphatidylinositol 3-kinase alpha is required for DNA synthesis
induced by some, but not all, growth factors. Proc Natl Acad Sci
USA. 91:9185–9189. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shivakrupa R, Bernstein A, Watring N and
Linnekin D: Phosphatidylinositol 3′-kinase is required for growth
of mast cells expressing the kit catalytic domain mutant. Cancer
Res. 63:4412–4419. 2003.PubMed/NCBI
|
|
16
|
Bondar VM, Sweeney-Gotsch B, Andreeff M,
Mills GB and McConkey DJ: Inhibition of the phosphatidylinositol
3′-kinase-AKT pathway induces apoptosis in pancreatic carcinoma
cells in vitro and in vivo. Mol Cancer Ther. 1:989–997.
2002.PubMed/NCBI
|
|
17
|
Hu H, Jiang C, Li G and Lü J: PKB/AKT and
ERK regulation of caspase-mediated apoptosis by methylseleninic
acid in LNCaP prostate cancer cells. Carcinogenesis. 26:1374–1381.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Schultz RM, Merriman RL, Andis SL,
Bonjouklian R, Grindey GB, Rutherford PG, Gallegos A, Massey K and
Powis G: In vitro and in vivo antitumor activity of the
phosphatidylinositol-3-kinase inhibitor, wortmannin. Anticancer
Res. 15:1135–1139. 1995.PubMed/NCBI
|
|
19
|
Hu L, Zaloudek C, Mills GB, Gray J and
Jaffe RB: In vivo and in vitro ovarian carcinoma growth inhibition
by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin
Cancer Res. 6:880–886. 2000.PubMed/NCBI
|
|
20
|
Semba S, Itoh N, Ito M, Harada M and
Yamakawa M: The in vitro and in vivo effects of
2-(4-morpholinyl)-8-phenyl-chromone (LY294002), a specific
inhibitor of phosphatidylinositol 3′-kinase, in human colon cancer
cells. Clin Cancer Res. 8:1957–1963. 2002.PubMed/NCBI
|
|
21
|
Minarini A, Milelli A, Fimognari C, Simoni
E, Turrini E and Tumiatti V: Exploring the effects of
isothiocyanates on chemotherapeutic drugs. Expert Opin Drug Metab
Toxicol. 10:25–38. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Cavell BE, Syed Alwi SS, Donlevy A and
Packham G: Anti-angiogenic effects of dietary isothiocyanates:
Mechanisms of action and implications for human health. Biochem
Pharmacol. 81:327–336. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma X, Fang Y, Beklemisheva A, Dai W, Feng
J, Ahmed T, Liu D and Chiao JW: Phenylhexyl isothiocyanate inhibits
histone deacetylases and remodels chromatins to induce growth
arrest in human leukemia cells. Int J Oncol. 28:1287–1293.
2006.PubMed/NCBI
|
|
24
|
Xiao L, Huang Y, Zhen R, Chiao JW, Liu D
and Ma X: Deficient histone acetylation in acute leukemia and the
correction by an isothiocyanate. Acta Haematol. 123:71–76. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Huang YQ, Ma XD, Zhen RJ, Chiao JW and Liu
DL: Experiment study of PHI on histone methylation and acetylation
in Molt-4 cells. Zhonghua Xue Ye Xue Za Zhi. 28:612–615. 2007.(In
Chinese). PubMed/NCBI
|
|
26
|
Jiang S, Ma X, Huang Y, Xu Y, Zheng R and
Chiao JW: Reactivating aberrantly hypermethylated p15 gene in
leukemic T cells by a phenylhexyl isothiocyanate mediated
inter-active mechanism on DNA and chromatin. J Hematol Oncol.
3:482010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zou Y, Ma X, Huang Y, Hong L and Chiao JW:
Effect of phenylhexyl isothiocyanate on aberrant histone H3
methylation in primary human acute leukemia. J Hematol Oncol.
5:362012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chiarini F, Del Sole M, Mongiorgi S,
Gaboardi GC, Cappellini A, Mantovani I, Follo MY, McCubrey JA and
Martelli AM: The novel Akt inhibitor, perifosine, induces
caspase-dependent apoptosis and downregulates P-glycoprotein
expression in multidrug-resistant human T-acute leukemia cells by a
JNK-dependent mechanism. Leukemia. 22:1106–1116. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wang L, Liu D, Ahmed T, Chung FL, Conaway
C and Chiao JW: Targeting cell cycle machinery as a molecular
mechanism of sulforaphane in prostate cancer prevention. Int J
Oncol. 24:187–192. 2004.PubMed/NCBI
|
|
30
|
Chou TC: Theoretical basis, experimental
design, and computerized simulation of synergism and antagonism in
drug combination studies. Pharmacol Rev. 58:621–681. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Beklemisheva AA, Fang Y, Feng J, Ma X, Dai
W and Chiao JW: Epigenetic mechanism of growth inhibition induced
by phenylhexyl isothiocyanate in prostate cancer cells. Anticancer
Res. 26:1225–1230. 2006.PubMed/NCBI
|
|
32
|
Lai YD, Ma XD, Huang YQ, Xu XN, Wang XZ,
Chiao DJ and Liu D: Modulation of histone acetylation and induction
of apoptosis in SMMC-7721 cells by phenylhexyl isothiocyanate.
Zhonghua Zhong Liu Za Zhi. 32:804–807. 2010.(In Chinese).
PubMed/NCBI
|
|
33
|
Osaki M, Oshimura M and Ito H: PI3K-Akt
pathway: Its functions and alterations in human cancer. Apoptosis.
9:667–676. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhuang Z, Ma X, Huang Y, Zheng Z, Zheng Y
and Jiang S: Study on histone acetylation modulation and Akt
signaling pathway inhibition by phenyhexyle isothiocyanate in
prostate cancer PC3 cell line. Chin J Urol. 31:707–709. 2010.
|
|
35
|
Kim D, Dan HC, Park S, Yang L, Liu Q,
Kaneko S, Ning J, He L, Yang H, Sun M, et al: AKT/PKB signaling
mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
West KA, Castillo SS and Dennis PA:
Activation of the PI3K/Akt pathway and chemotherapeutic resistance.
Drug Resist Updat. 5:234–248. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Martelli AM, Tabellini G, Bortul R,
Tazzari PL, Cappellini A, Billi AM and Cocco L: Involvement of the
phosphoinositide 3-kinase/Akt signaling pathway in the resistance
to therapeutic treatments of human leukemias. Histol Histopathol.
20:239–252. 2005.PubMed/NCBI
|
|
38
|
Luo J, Manning BD and Cantley LC:
Targeting the PI3K-Akt pathway in human cancer: Rationale and
promise. Cancer Cell. 4:257–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Huang WC and Chen CC: Akt phosphorylation
of p300 at Ser-1834 is essential for its histone acetyltransferase
and transcriptional activity. Mol Cell Biol. 25:6592–6602. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Rohde JR and Cardenas ME: The tor pathway
regulates gene expression by linking nutrient sensing to histone
acetylation. Mol Cell Biol. 23:629–635. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Denlinger CE, Rundall BK and Jones DR:
Inhibition of phosphatidylinositol 3-kinase/Akt and histone
deacetylase activity induces apoptosis in non-small cell lung
cancer in vitro and in vivo. J Thorac Cardiovasc Surg.
130:1422–1429. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang X, Sun DF and Fang JY: Research
advances on the relationship of PI3-kinase/Akt/mTOR pathway and
epigenetic modification. Yi Chuan. 28:1585–1590. 2006.(In Chinese).
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Wei FZ, Cao Z, Wang X, Wang H, Cai MY, Li
T, Hattori N, Wang D, Du Y, Song B, et al: Epigenetic regulation of
autophagy by the methyltransferase EZH2 through an MTOR-dependent
pathway. Autophagy. 11:2309–2322. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Nishioka C, Ikezoe T, Yang J, Koeffler HP
and Yokoyama A: Blockade of mTOR signaling potentiates the ability
of histone deacetylase inhibitor to induce growth arrest and
differentiation of acute myelogenous leukemia cells. Leukemia.
22:2159–2568. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Gan YH and Zhang S: PTEN/AKT pathway
involved in histone deacetylases inhibitor induced cell growth
inhibition and apoptosis of oral squamous cell carcinoma cells.
Oral Oncol. 45:e150–e154. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sakamoto K, Iwasaki K, Sugiyama H and
Tsuji Y: Role of the tumor suppressor PTEN in antioxidant
responsive element-mediated transcription and associated histone
modifications. Mol Biol Cell. 20:1606–1617. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Pan L, Lu J, Wang X, Han L, Zhang Y, Han S
and Huang B: Histone deacetylase inhibitor trichostatin a
potentiates doxorubicin-induced apoptosis by up-regulating PTEN
expression. Cancer. 109:1676–1688. 2007. View Article : Google Scholar : PubMed/NCBI
|
